Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Burles Avner Johnson"'
Autor:
Evangelia Vlachou, Burles Avner Johnson, David McConkey, Yuezhou Jing, Andres Matoso, Noah M. Hahn, Jean Hoffman-Censits
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
IntroductionEnfortumab vedotin (EV) is an antibody drug conjugate approved for advanced urothelial cancer, consisting of a monomethyl auristatin E payload linked to a human monoclonal antibody targeting nectin-4. No validated biomarker predictive of
Externí odkaz:
https://doaj.org/article/1f0b6a04324d4a688f636d0b106bf1d8
Autor:
Evangelia Vlachou, Andres Matoso, David McConkey, Yuezhou Jing, Burles Avner Johnson, 3rd, Noah M. Hahn, Jean Hoffman-Censits
Publikováno v:
European Urology Open Science, Vol 49, Iss , Pp 100-103 (2023)
Enfortumab vedotin (EV) is an antibody-drug conjugate approved for the treatment of refractory advanced urothelial cancer. Cutaneous toxicity is well described but has not been correlated with response. In this retrospective single-center study, data
Externí odkaz:
https://doaj.org/article/b433314c102d453b9d1b9b99d3eb8105
Autor:
Burles Avner Johnson, Mingxiao Feng, Woonyoung Choi, Gabriela Colocho, Alyssa Arbuiso, Samuel Jin, Adam K. Aragaki, Charles Ruland, Stanley Rapiey, Noah M. Hahn, David J. McConkey
Publikováno v:
Cancer Research. 83:612-612
Introduction: Developing optimized bladder cancer mouse models that can be used in the evaluation of immune based therapeutics remains a high priority in ongoing research.Experimental Procedures: In previous work by our collaborators, murine cell lin
Autor:
Evangelia Vlachou, Noah M. Hahn, Alix Dabb, Burles Avner Johnson, M. Susan Lefande, Jean H. Hoffman-Censits
Publikováno v:
Journal of Clinical Oncology. 41:523-523
523 Background: In the TROPHY study, 8.8% of the 113 patients (pts) were enrolled post EV treatment, with ORR to SG of 30% in that small subset. Response to SG post EV in real world populations has not been previously reported. SG has accelerated FDA
Autor:
Jean H. Hoffman-Censits, Burles Avner Johnson, Noah M. Hahn, Woonyoung Choi, Armine Smith, Nirmish Singla, David James McConkey, Max R. Kates
Publikováno v:
Journal of Clinical Oncology. 41:TPS599-TPS599
TPS599 Background: Small cell bladder cancer (SCBC) is a rare aggressive bladder cancer (BC) variant comprising